Report Overview

Global Pneumonia Therapeutics Market – Market Outlook & Trends

The Global PneumoniaTherapeutics Market valued at USD 1.7 billion in 2019, is expected to reach USD 2.84 billion by 2026, at a CAGR of 7.60% during the projection period. The worldwide pneumonia therapeutics market is growing due to rising air pollution and increasing the geriatric population across the world. Numerous environmental wastes like chemicals spread harmful microorganisms such as fungi, viruses, and bacteria, which cause pneumonia. Most of the pharmaceutical companies undertake substantial research activities for the development of novel drugs, enhancing market growth. Besides, rapid urbanization and industrialization, advanced levels of air pollution, unhealthy routine, and growing smoking populace have increased the cases of asthma and pneumonia in urban areas. It leads to the increasing demand for pneumonia therapeutics, thereby fueling the growth of the Global Pneumonia Therapeutics Market. However, the lack of consciousness among the citizens about its drug & cure and traditional treatment for pneumonia may restrain the development of the pneumonia therapeutics market in the prospect.

Global Pneumonia Therapeutics Market – Overview 

Pneumonia is a seditious disorder disturbing the air sacs or alveoli in the lungs, and it may lead to fever, dry cough, chest pain, breathing trouble, etc. It is usually caused by germs and bacteria and mostly afflicts the person suffering from cold and flu. It can be life-threatening for young children, infants, and older adults. It can be detected with the help of blood tests, X-rays, physical examinations, etc. Vaccination helps avoid pneumonia, whereas patients with critical situations, patients need to be hospitalized and help with oxygen therapy. Generally, antibiotics like quinolones, macrolides, etc. are used for treating pneumonia.

Growth Drivers 

Surging Cases of Pneumonia across the Globe

The unhealthy lifestyle and polluted atmosphere enhance the prevalence of pneumonia across different age-groups of population. Besides, Geriatric or senior citizens are vulnerable to pneumonia due to weak immune systems. Heart disease, diabetes, and other serious diseases are very communal in ageing persons, which eventually raises the risk of pneumonia. The geriatric section accounted for around 20% market share in 2019 and is projected to rise over the forecast period. Also, the geriatric population base is prone to get affected by flu and other lung-related disorders that sometimes grow into pneumonia.

Favorable government initiatives in the Asia Pacific Region 

Asia Pacific pneumonia therapeutics market held a substantial revenue share of 34% in 2019 due to growing cases of pneumonia. Governments of various nations are committed to reducing the prevalence of pneumonia with substantial investment outlay and remedial measures, which is anticipated to enhance the market growth for the therapeutics. 

Increasing R&D Outlay for New Product Development 

The private and state players are allocating more and more outlay for R & D, emphasizing effective therapeutics. Currently, the market is witnessing a significant number of new product launches, driving the market growth. The major companies in pneumonia therapeutics market such as Sanofi, Eli Lilly, AstraZeneca, Merck & Co. Novartis, GlaxoSmithKline, Pfizer, and Baxter International Inc. invest substantially in research applications for developing novel drugs and diagnostic methods.

Impact of COVID-19 in industry

The main causes of COVID-19 are cough and sneeze, and people at large want to mitigate these symptoms or causes at the earliest. They tend to consume the remedial drugs to get cured, which again enhances the market for cough or flu subsiding drugs. In the wake of coronavirus, the pharmaceutical industry has received a major boost, assuring the substantial market growth during the forthcoming period.

Global Pneumonia Therapeutics Market: Segmentation

Global Pneumonia Therapeutics Market is segmented on Drug Class (Antibacterial, Antiviral, Antifungal), Age Group (Pediatric, Adult, Geriatric), Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

In Drug Class, the Antiviral drugs market segment is anticipated to witness approximately 7.5% CAGR during the forecast period, due to increasing viral pneumonia which spreads from the fluid present in the air dews after distinct coughs or sneezes. Various remedial options, including Oseltamivir and Acyclovir, are available to give the antiviral contamination and diminish the severity of flu viruses into the body. These options are expected to induce market growth.

Based on the infection type, the HAP market accounted for more than USD 352 Million in 2019 and is expected to grow with the rising hospital stays during the forthcoming period. Hospital-acquired pneumonia is a lung contamination that occurs during hospital stays, which leads to serious issues such as renal failure, respiratory failure, and empyema. Increasing incidences of hospital-acquired pneumonia will induce the request for pneumonia therapeutics drugs.

Based on Distribution Channel, the online pharmacies market will display around 8% CAGR throughout the prediction timeframe. Online pharmacies are better than offline stores in terms of low product and transaction costs. Moreover, online pharmacies offer suitability and convenience to persons with restricted mobility. Furthermore, these pharmacies provide doorstep distribution within a short period that surges their fondness. The factors mentioned above are likely to drive growth in the online segment during the projection timeframe.

Based on region, Global Pneumonia Therapeutics Market is segmented by key regions— North America, Europe, Asia Pacific, South America, and the Middle East & Africa. 

Global Pneumonia Therapeutics Market: Regional Insights 

The markets in North America and Europe hold vital market share because of well-developed healthcare sector, increasing occurrences of community-acquired pneumonia, and presence of well-known players operating in the target market through various countries in this region. The market in the Asia Pacific is anticipated to see the fastest growth, owing to growing government spending on healthcare and the presence of leading players in the developing economies such as India and China in this region.

Competitive Landscape

The leading players considered for market analysis are Abbott Laboratories, Allergan, AstraZeneca, Bayer, Cipla, GlaxoSmithKline, Lupin Pharmaceuticals, Merck, Mylan, Novartis, Pfizer, Sanofi and other prominent players.

Recent Development

Ø  In September 2018, Pfizer received breakthrough therapy designation from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine. This vaccine is useful for the prevention of pneumonia and invasive diseases. The development has enhanced the market position and portfolio of the company.

Ø  In June 2019, Merck received FDA approval for Zerbaxa drug, used in the treatment of ventilator-associated pneumonia and hospital-acquired bacterial pneumonia. It has widened the firm’s pneumonia therapeutics portfolio.

Scope of the Report

By Drug Class

Ø  Antibacterial Drugs

ü  Macrolide

ü  Quinolones

Ø  Antiviral Drugs

Ø  Antifungal Drugs

By Age Group

Ø  Pediatric

Ø  Adult

Ø  Geriatric 

By Infection Type

Ø  Hospital-acquired Pneumonia [HAP]

Ø  Community-acquired Pneumonia [CAP]

Ø  Ventilator-associated Pneumonia [VAP]

By Distribution Channel

Ø  Hospital Pharmacies

Ø  Retail Pharmacies

Ø  Online Pharmacies 

By Region

Ø  North America

Ø  Europe 

Ø  Asia Pacific

Ø  South America

Ø  Middle East & Africa

The objective of the Study:

Ø  To analyze and estimate the Global Pneumonia Therapeutics Market size, in terms of value.

Ø  To examine the market segmentation carefully and estimate the market size, in terms of value, based on the region by segmenting the Global Pneumonia Therapeutics Market into five regions, namely, North America, Europe, Asia Pacific, Rest of the World and their leading countries.

Ø  To outline, categorize and project the Global Pneumonia Therapeutics Market based on the Drug Class, Age Group, Infection Type, Distribution Channel and Region.

Ø  To examine competitive developments in drugs, diagnostics, and distribution channels within the Global Pneumonia Therapeutics Market.

Ø  To highlight market dynamics such as drivers, restraints, opportunities, and challenges and their impact.

Ø  To provide a detailed competitive landscape, including major players, their strategic profiles, and market shares.

Business Questions Answered by the Report

Ø  How will the market drivers, restraints, and opportunities affect the market dynamics?

Ø  What will be the market size in terms of value and volume and market statistics with a detailed classification?

Ø  Which segment dominates the market or region, and which one will be the fastest-growing, and why?

Ø  Who are the key players in the market, and what is their share?

Ø  What is the strategy adopted by key players, and how does it affect the existing and new players?

Customization Scope for the Client

Client satisfaction is our first and last priority, and that is why BlueWeave Consulting offers customization as per client’s specific needs. The following customization options are available for the report:

Ø  Additional Company Information

Ø  Detail Analysis of five additional companies

Ø  Additional country analysis

Ø  Detailed segment analysis

Recent healthcare Reports: Global | Regional || Medical Devices

1.    Resarch Framework

1.1.     Research Objective

1.2.     Product Overview

1.3.     Market Segmentation

2.    Research Methodology

2.1.     Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2.     Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3.     Market Breakdown & Data Triangulation

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4.     Breakdown of Primary research respondent, By Region

2.5.     Assumption & Limitation

3.    Executive Summary

4.    Global Pneumonia Therapeutics market Industry Insights

4.1.     Industry Value Chain Analysis

4.2.     DROC Analysis

4.2.1.   Growth Drivers

4.2.2.   Restraint

4.2.3.   Opportunities

4.2.4.   Challenges

4.3.     Technological Landscape/Recent Development

4.4.     Regulatory Framework

4.5.     Company Market Share Analysis, 2019

4.6.     Porter’s Five Forces Analysis

4.6.1.   Bargaining Power of Suppliers

4.6.2.   Bargaining Power of Buyers

4.6.3.   Threat of New Entrants

4.6.4.   Threat of Substitutes

4.6.5.   Intensity of Rivalry

4.7.     Impact of COVID 19

5.    Global Pneumonia Therapeutics market Overview

5.1.     Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Million)

5.2.     Market Share & Forecast

5.2.1.   By Drug Class

5.2.1.1.       Antibacterial Drugs

5.2.1.1.1.          Macrolide

5.2.1.1.2.          Quinolones

5.2.1.2.       Antiviral Drugs

5.2.1.3.       Antifungal Drugs

5.2.2.   By Age group

5.2.2.1.       Pediatric

5.2.2.2.       Adult

5.2.2.3.       Geriatric

5.2.3.   By infection

5.2.3.1.       Hospital-acquired Pneumonia [HAP]

5.2.3.2.       Community-acquired Pneumonia [CAP]

5.2.3.3.       Ventilator-associated Pneumonia [VAP]

5.2.4.   By Distribution Channel   

5.2.4.1.       Hospital Pharmacies

5.2.4.2.       Retail Pharmacies

5.2.4.3.       Online Pharmacies

5.2.5.   By Region

5.2.5.1.   North America

5.2.5.2.   Europe

5.2.5.3.   Asia Pacific

5.2.5.4.   Latin America

5.2.5.5.   Middle East & Africa

6.    North America Pneumonia Therapeutics Market

6.1.     Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Million)

6.2.     Market Share & Forecast

6.2.1.   By Drug Class

6.2.2.   By Age group

6.2.3.   By infection

6.2.4.   By Distribution Channel

6.2.5.   By Country

6.2.5.1.     United States

6.2.5.2.     Canada

7.    Europe Pneumonia Therapeutics market

7.1.     Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Million)

7.2.     Market Share & Forecast

7.2.1.   By Drug Class

7.2.2.   By Age group

7.2.3.   By infection

7.2.4.   By Distribution Channel

7.2.5.   By Country

7.2.5.1.     Germany

7.2.5.2.     United Kingdom

7.2.5.3.     France

7.2.5.4.     Italy

7.2.5.5.     Spain

7.2.5.6.     Rest of Europe

8.    Asia Pacific Pneumonia Therapeutics Market

8.1.     Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Million)

8.2.     Market Share & Forecast

8.2.1.   By Drug Class

8.2.2.   By Age group

8.2.3.   By infection

8.2.4.   By Distribution Channel

8.2.5.   By Country

8.2.5.1.       India

8.2.5.2.       China

8.2.5.3.       Japan

8.2.5.4.       South Korea

8.2.5.5.       Rest of Asia Pacific

9.    Latin America Pneumonia Therapeutics Market

9.1.     Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Million)

9.2.    Market Share & Forecast

9.2.1.1.       By Drug Class

9.2.1.2.       By Age group

9.2.1.3.       By infection

9.2.1.4.       By Distribution Channel

9.2.1.5.       By Country

9.2.1.5.1.          Brazil

9.2.1.5.2.          Mexico

9.2.1.5.3.          Rest of Latin America

10.Middle East & Africa Pneumonia Therapeutics Market

10.1.   Market Size & Forecast by Value, 2016-2026

10.1.1.                By Value (USD Million)

10.2. Market Share & Forecast

10.2.1.1.    By Drug Class

10.2.1.2.    By Age group

10.2.1.3.    By infection

10.2.1.4.    By Distribution Channel

10.2.1.5.    By Country

10.2.1.5.1.       Saudi Arabia

10.2.1.5.2.       UAE

10.2.1.5.3.       South Africa

10.2.1.5.4.       Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

11.1. Abbott Laboratories

11.2. Allergan

11.3. AstraZeneca

11.4. Bayer

11.5. Cipla

11.6. GlaxoSmithKline

11.7.  Lupin Pharmaceuticals

11.8.  Merck

11.9.  Mylan

11.10. Novartis

11.11. Pfizer

11.12. Sanofi

11.13 Other Prominent Players

* Financial details in case of unlisted companies will be available as per data availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.